AMTB hydrochloride
Based on 2 publication(s) in Google Scholar
AMTB hydrochloride is a selective TRPM8 channel blocker. AMTB hydrochloride inhibits icilin-induced TRPM8 channel activation with a pIC50 of 6.23. AMTB hydrochloride can be used for the research of the overactive bladder and painful bladder syndrome. AMTB hydrochloride is a non-selective inhibitor of voltage-gated sodium channels (NaV).
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.08%
- CAS No.: 926023-82-7
- Formule: C23H27ClN2O2S
- Masse moléculaire:430.99
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-15064
HC-030031TRP Channel Inhibitor -
HY-11062
IcilinTRPM8 Agonist -
HY-108449
AcoltremonTRPM8 agonist -
HY-101736
AMG9810TRPV1 Antagonist -
HY-12245
SB-366791VR1/TRPV1 Antagonist -
HY-108463
A-967079TRPA1 Receptor Antagonist -
HY-12949
ML204TRPC4/TRPC5 Channel Inhibitor -
HY-18662
RQ-00203078TRPM8 Antagonist -
HY-108457
9-PhenanthrolTRPM4 Inhibitor -
HY-19975
RN-1734TRP Channel Antagonist -
HY-108451
OnonetinTRPM3 Blocker -
HY-75161
(-)-MentholEndogenous Metabolite
Publications Citing Use of MedChemExpress (MCE) AMTB hydrochloride
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.414 μM
Compound: 2; AMTB
|
Antagonist activity at human recombinant TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-induced calcium increase by Fluo-4 AM based assay
Antagonist activity at human recombinant TRPM8 expressed in HEK293 cells assessed as inhibition of menthol-induced calcium increase by Fluo-4 AM based assay
|
[PMID: 27964995] |
| HEK293 | IC50 |
0.448 μM
Compound: 2; AMTB
|
Antagonist activity at human recombinant TRPM8 expressed in HEK293 cells assessed as inhibition of icilin-induced calcium increase by Fluo-4 AM based assay
Antagonist activity at human recombinant TRPM8 expressed in HEK293 cells assessed as inhibition of icilin-induced calcium increase by Fluo-4 AM based assay
|
[PMID: 27964995] |
In Vitro
AMTB hydrochloride blocks veratridine-induced membrane potential changes at each NaV1 isoform (pIC50s ranging 4.83-5.69 for NaV1.1- NaV1.8)[2].
AMTB hydrochloride decreases viable cell number in MDA-MB-231 and SK-BR-3 breast cancer cell lines (30 and 100 μM), and also reduces the migration of MDA-MB-231 cells (30 μM)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 926023-82-7
-
Appearance Solid
-
Masse moléculaire 430.99
-
Formule C23H27ClN2O2S
-
Color White to off-white
-
SMILES
O=C(N(CCCN)CC1=CC=CS1)C2=CC=CC=C2OCC3=CC=CC(C)=C3.[H]Cl
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
2024 Mar 25:322:117581. PMID: 38103845 -
BMC Cancer
Enhanced anti-cancer effect of AMTB hydrochloride via chitosan nanoparticles in pancreatic cancer. [Abstract]2025 May 26;25(1):944. PMID: 40420025
Solvant et solubilité
In Vitro:
DMSO : 100 mg/mL (232.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.80 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Lashinger ES, et al. AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol. 2008;295(3):F803-F810. [Content Brief]
[2]. Yapa KTDS, et al. Assessment of the TRPM8 inhibitor AMTB in breast cancer cells and its identification as an inhibitor of voltage gated sodium channels. Life Sci. 2018;198:128-135. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3202 mL | 11.6012 mL | 23.2024 mL | 58.0060 mL |
| 5 mM | 0.4640 mL | 2.3202 mL | 4.6405 mL | 11.6012 mL | |
| 10 mM | 0.2320 mL | 1.1601 mL | 2.3202 mL | 5.8006 mL | |
| 15 mM | 0.1547 mL | 0.7734 mL | 1.5468 mL | 3.8671 mL | |
| 20 mM | 0.1160 mL | 0.5801 mL | 1.1601 mL | 2.9003 mL | |
| 25 mM | 0.0928 mL | 0.4640 mL | 0.9281 mL | 2.3202 mL | |
| 30 mM | 0.0773 mL | 0.3867 mL | 0.7734 mL | 1.9335 mL | |
| 40 mM | 0.0580 mL | 0.2900 mL | 0.5801 mL | 1.4501 mL | |
| 50 mM | 0.0464 mL | 0.2320 mL | 0.4640 mL | 1.1601 mL | |
| 60 mM | 0.0387 mL | 0.1934 mL | 0.3867 mL | 0.9668 mL | |
| 80 mM | 0.0290 mL | 0.1450 mL | 0.2900 mL | 0.7251 mL | |
| 100 mM | 0.0232 mL | 0.1160 mL | 0.2320 mL | 0.5801 mL |
AMTB hydrochloride Related Classifications
HY-100345 Related Classifications
Powered by Bioz